VRd vs KRd for newly diagnosed multiple myeloma
ENDURANCE study
Background: Carfilzomib, a second-generation proteasome inhibitor showed deep responses in patients with newly diagnosed multiple myeloma in several phase 2 studies indicating that it might be the “better” option compared to a bortezomib based regimen. ENDURANCE was a phase 3 clinical trial directly comparing carfilzomib, revlimid and dexamethasone (KRd…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.